Ganoderic acid A

Catalog No.S4753 Batch:S475301

Print

Technical Data

Formula

C30H44O7
Molecular Weight 516.67 CAS No. 81907-62-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (193.54 mM)
Ethanol 100 mg/mL (193.54 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ganoderic acid A (GAA), a representative active triterpenoid from Ganoderma lucidum, has been reported to exhibit antinociceptive, antioxidative, cytotoxic, hepatoprotective and anticancer activities.
In vitro GAA exhibits antitumor activity on human osteosarcoma, lymphoma, meningioma and breast cancer cells through suppressing growth and invasive behavior and/or inducing apoptosis of cancer cells. GAA could also enhance chemosensitivity of HepG2 cells to Cisplatin[1]. GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. Lower doses of GA-A enhance HLA class II-mediated antigen presentation and CD4+ T cell recognition of lymphoma in vitro[2].
In vivo GAA can significantly prolong the survival of EL4 syngeneic mice and decrease tumor metastasis to the liver, and enhance cell-mediated immune responses by attenuating myeloid-derived suppressor cells. GAA could undergo extensive metabolism, including reduction, oxidation, and hydroxylation phase I metabolism, and glucuronidation and sulfation phase II metabolism[1].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Human pre-B acute lymphocytic leukemia (NALM-6), Burkitt lymphoma (Ramos, GA-10, CA-46 and Daudi) and non-Hodgkin

  • Concentrations

    5, 10, 20, and 40μM

  • Incubation Time

    24 h

  • Method

    Cells are seeded at 1×104 cells/well in 100μl of appropriate culture medium in a flat-bottom 96-well plate. GA-A is added to appropriate wells for final concentrations of 5, 10, 20, and 40μM. Following 24h of GA-A treatment, cell viability is measured using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS).
Animal Study:

[1]
  • Animal Models

    Male Sprague-Dawley rats

  • Dosages

    20 mg/kg

  • Administration

    i.v.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.